Factors Associated with Quality of Life in Chronic Hepatitis C Patients Who Received Interferon Plus Ribavirin Therapy
Shu‐Chuan Chang, Sheng‐Shun Yang(Taichung Veterans General Hospital), Wang‐Sheng Ko(Kuang Tien General Hospital), Cheng‐Yuan Peng(China Medical University), Shun-Sheng Wu(Changhua Christian Hospital)
Cited by 14
Related Papers
Mitotic and G <sub>2</sub> Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216
|Science|1997|1.3k
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma
|Journal of Clinical Oncology|2018|653
Elbasvir–Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy
|Annals of Internal Medicine|2016|364
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study
|The Lancet|2014|343
Cyclin A/CDK2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation.
|Molecular and Cellular Biology|1994|284